EPO Patent Bulletin: Assays for Diagnosing Fabry Disease Treatment Options

The European Patent Office has published patent application EP4541418A2 concerning assays for diagnosing and evaluating treatment options for Fabry disease. The application lists Amicus Therapeutics, Inc. and the National Institutes of Health as applicants.

EPO Patent Application: Metformin and Sitagliptin Tablet Formulation

The European Patent Office published patent application EP4563143A1 concerning a bilayer tablet formulation of Metformin and Sitagliptin that includes an antioxidant. The application was filed by Sanovel Ilac Sanayi ve Ticaret A.S. and lists Fatih Sunel, Nur Pehlivan Akalin, and Guldeniz Tunc as inventors.

EPO Patent: Neural Disorder Treatment via Plasminogen Cascade Modulation

The European Patent Office has published a patent application (EP2024194382A1) detailing methods for preventing or treating neural disorders by modulating the plasminogen-plasmin cascade. The patent application was published on March 18, 2026, and covers designated states within the European Union.

EPO Patent Publication: Phyto-Compositions

The European Patent Office published patent application EP4661839A1 for Phyto-Compositions on March 18, 2026. The applicant is Phytoheal Medtech International. This publication details new compositions and their potential applications.

Pfizer Inc. Patent on Nucleic Acids for Therapeutic Uses

The European Patent Office has published patent application EP4661903A1 by Pfizer Inc. concerning nucleic acids for therapeutic uses. This publication details specific nucleic acid sequences and their applications, potentially impacting future drug development and intellectual property within the EU.

EPO Patent: P38 Map Kinase Inhibitors for Cancer Immunotherapy

The European Patent Office has published patent application EP4648772A1 concerning P38 map kinase inhibitors for use in treating cancer immunotherapy-associated cytokine release syndrome. The patent is assigned to Poolbeg Pharma (UK) Limited.

EPO Patent Filing: HIV-Neutralizing Antibodies by Theraclone Sciences

The European Patent Office (EPO) has published a patent application (EP4549461A2) filed by Theraclone Sciences, Inc., The Scripps Research Institute, and International AIDS Vaccine Initiative for HIV-neutralizing antibodies. The patent publication date is March 18, 2026.

EPO Patent: New Therapeutic Combinations for Progressive Fibrosing Lung Diseases

The European Patent Office has published patent application EP4520394A2 concerning new therapeutic combinations for treating progressive fibrosing interstitial lung diseases. The patent was filed by Boehringer Ingelheim International GmbH and lists multiple inventors. The publication date is March 18, 2026.

EPO Patent Publication: Enhancing Vaccine Immunogenicity

The European Patent Office has published patent application EP4509185A2 concerning methods for enhancing the immunogenicity of vaccines using oral yeast beta-glucans. The patent application lists Memorial Sloan Kettering Cancer Center as the applicant.

EPO Patent: Kinase Inhibitors for Nervous System Disorders

The European Patent Office has published patent application EP4574153A2 concerning kinase inhibitors for treating central and peripheral nervous system disorders. The patent application lists the University of Miami as the applicant and includes specific IPC classifications related to chemical compounds and their therapeutic applications.